GH Research PLC (NASDAQ:GHRS – Free Report) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for GH Research in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings per share of ($1.72) for the year. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.
GH Research (NASDAQ:GHRS – Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.42.
Read Our Latest Research Report on GHRS
GH Research Trading Up 7.4%
GHRS opened at $13.79 on Tuesday. The firm has a market cap of $717.47 million, a P/E ratio of -17.46 and a beta of 0.97. GH Research has a 12 month low of $6.00 and a 12 month high of $20.50. The stock has a 50-day moving average of $10.59 and a 200 day moving average of $10.33.
Institutional Trading of GH Research
Several institutional investors have recently added to or reduced their stakes in GHRS. Cormorant Asset Management LP boosted its position in GH Research by 238.8% in the 1st quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company’s stock valued at $22,165,000 after buying an additional 1,416,439 shares during the period. Alyeska Investment Group L.P. purchased a new stake in shares of GH Research during the 1st quarter worth $5,018,000. RA Capital Management L.P. lifted its position in shares of GH Research by 3.9% during the 1st quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company’s stock worth $76,599,000 after purchasing an additional 257,959 shares during the last quarter. Troluce Capital Advisors LLC purchased a new stake in shares of GH Research during the 1st quarter worth $1,716,000. Finally, Walleye Capital LLC purchased a new stake in shares of GH Research during the 1st quarter worth $584,000. Institutional investors and hedge funds own 56.90% of the company’s stock.
GH Research Company Profile
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
See Also
- Five stocks we like better than GH Research
- Insider Trading – What You Need to Know
- Is Consumer Discretionary a Dead End? These 3 Stocks Say No
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive?
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.